MedTrace Logo

Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.

NCT04625985 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-04-08

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of the metformin glycinate and standard treatment of the hospital in hospitalized patients with Severe Acute Respiratory Syndrome secondary to SARS-CoV2.

Conditions

  • Severe Acute Respiratory Syndrome Coronavirus 2

Interventions

DRUG

Metformin Glycinate

Participants randomized to metformin glycinate will take 620 mg bid (PO) for 14 days plus standard treatment

DRUG

Placebo oral tablet

Participants randomized to placebo will take a tablet bid (PO) for 14 days in plus standard treatment

Sponsors & Collaborators

  • Laboratorios Silanes S.A. de C.V.

    lead INDUSTRY

Principal Investigators

  • Janet Silvia M Aguirre, MD · The American British Cowdray Medical Center. I.A.P.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-14
Primary Completion
2021-03-08
Completion
2021-03-18

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04625985 on ClinicalTrials.gov